6c3fd2dd__Trials_Monthly___October_2013__Description
[NCI Designation] NCT01884285 [Disease Site] Prostate, Lung, Breast Cancer [Description] 
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castrate-Resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-Deficient Advanced Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186 within Prospectively-validated PTEN Deficient Tumours
Seattle Cancer Care Alliance | Clinical Trials Monthly - October 2013
Description